reports
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024 Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements...
PCI Biotech Holding ASA - Annual Report 2023
PCI Biotech Holding ASA - Annual Report 2023 Oslo, Norway, April 26, 2024.The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, , Mobile: 757This information is subject to the disclosure requirements pursuant to section 5...
PCI Biotech second half 2023 interim results
PCI Biotech second half 2023 interim results Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was initiation of field testing in Q4 with an internat...
PCI Biotech: Invitation to second half interim 2023 results presentati...
PCI Biotech: Invitation to second half interim 2023 results presentation Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made availab...
PCI Biotech initiates field testing of its proprietary technology for ...
PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies. The partners have signed a collaborative research agreement with the purpose of testing PCI Biotech’s proprietary technology for gene therapy manufacturing in the partners’ pilot manufacturing process. PCI Biotech brings its novel and promising technology for viral vector manufacturing into the field testi...
PCI Biotech: European patent for mRNA delivery with fimaNAc
PCI Biotech: European patent for mRNA delivery with fimaNAc Oslo (Norway), 7 September 2023 – PCI Biotech (OSE: PCIB), a biopharmaceutical company, today announces that the European Patent Office (EPO) has informed PCI Biotech that they intend to grant a new patent covering delivery of mRNA by use of PCI Biotech’s fimaNAc technology. This application is primarily foreseen to be used for dermatology. Nucleic acid therapeutics, including mRNAs, have the potential to improve the treatment of dermatological diseases, but delivery to skin lesions remains an obstacle. This is a challenge PCI Bio...
PCI Biotech: Employee share option scheme
PCI Biotech: Employee share option scheme Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 25 May 2023 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 700,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), a...
PCI Biotech: Write-down of share capital registered
PCI Biotech: Write-down of share capital registered Oslo, Norway, 1 September 2023 – PCI Biotech Holding ASA (OSE: PCIB) Reference is made to the resolution made by the Annual General Meeting 25 May 2023, in respect of a write-down of share capital by reducing the par value of PCI Biotech Holding ASA’s shares from NOK 3.00 to NOK 0.03. Parts of the share capital reduction amount shall be used to cover loss that cannot be covered in any other way and the residual of the reduction amount shall be transferred to other equity. The capital reduction was registered in the Norwegian Register of ...
PCI Biotech first half 2023 interim results
PCI Biotech first half 2023 interim results Oslo (Norway), 31 August 2023 – PCI Biotech (OSE: PCIB), today announces its interim first half 2023 results. Please find enclosed the report and presentation.Highlights review fimaNAc – bioprocessingThe bioprocessing program for use of fimaNAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Continued focus on generating results that can trigger field testing with potential customers to get feedback and develop a competitive technology. fimaNAc – dermatologyFor dermatology the ...
PCI Biotech: Invitation to first half interim 2023 results presentatio...
PCI Biotech: Invitation to first half interim 2023 results presentation Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2023 interim report on Thursday 31 August 2023, 08:30am – 09:30am CEST (local time). The presentation will be held as a live webcast and can be accessed through There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset (CSO), and Morten Luhr (BD M...
Minutes from Annual General Meeting 2023
Minutes from Annual General Meeting 2023 Oslo, 25 May 2023. The Annual General Meeting in PCI Biotech Holding ASA took place today, 25 May 2023. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment ...
Disclosure of voting rights for Chairman of the Board
Disclosure of voting rights for Chairman of the Board Oslo, 24 May 2023. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 25 May 2023. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 5,590,554 additional shares. In total, Mr. Bøhn will represent and vote for 15.3 per cent of the share capital. A major...
PCI Biotech interim Q1 2023 results
PCI Biotech interim Q1 2023 results Oslo (Norway), 12 May 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q1 2023 results. Please find enclosed the report and presentation. Highlights reviewfimaNAc – bioprocessingThe bioprocessing program for use of fimaNAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Upcoming work will focus on generating results that can trigger testing with potential customers to get feedback and develop a competitive technology. fimaNAc – dermatologyThe run-in phase of the...
PCI Biotech: Invitation to Q1 2023 results presentation
PCI Biotech: Invitation to Q1 2023 results presentation Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time). The presentation will be held as a live webcast and can be accessed through There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset (CSO), and Morten Luhr (BD Manager), and the presentation will ...
PCI Biotech - Notice of Annual General Meeting 2023
PCI Biotech - Notice of Annual General Meeting 2023 Oslo, Norway 4 May 2023 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2023 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements pursuant to sectio...
PCI Biotech Holding ASA: Annual Report 2022
PCI Biotech Holding ASA: Annual Report 2022 Oslo, Norway, April 28, 2023The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2022. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2022 is also available on the company’s website For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, , Mobile: 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwe...
PCI Biotech interim Q4 2022 results
PCI Biotech interim Q4 2022 results Oslo (Norway), 17 February 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q4 2022 results. Please find enclosed the report and presentation. Highlights fimaNAc – dermatology and bioprocessing*The first phase of the dermatology program, to demonstrate topical fimaNAc-mediated nucleic acid delivery in a preclinical wound model, is on track for readout 1H 2023. Positive results will be utilised for seeking co-development with partners having nucleic acid-based drug candidates *The bioprocessing program has matured, and the first patent applic...
PCI Biotech: Invitation to Q4 2022 results presentation
PCI Biotech: Invitation to Q4 2022 results presentation Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session. The company will...
Flaggemelding relatert til PCIB
Flaggemelding relatert til PCIB Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge av salget innehar Myrlid AS etter dette totalt 1 450 000 aksjer og stemmer i Selskapet direkte, samt eierskap til ytterligere 400 000 aksjer gjennom sitt 50 % eierskap i Jandersen Kapital AS, totalt sett tilsvarer dette ca. 4,95 % av aksjene og stemmene i Selskapet.
PCI Biotech: Employee share option scheme
PCI Biotech: Employee share option scheme Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 25 May 2022 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 570,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.